CBV protocol

chemotherapy protocol consisting of above cpds; used in treatment of lymphoma; do not confuse with VP-16, HSV-1 protein

Also Known As:

BEC 2 protocol; BEC-2 protocol; CVB regimen; IAPVP-16 protocol; VP-16 protocol

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - CBV protocol: 4
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - CBV protocol: 4
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - CBV protocol: 4
Organic Chemicals: 133
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        CBV protocol: 4
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - Etoposide: 10706
      - CBV protocol: 4

Experts

1.	Gu, J L: 1 article (09/2019)
2.	Huang, B H: 1 article (09/2019)
3.	Li, J: 1 article (09/2019)
4.	Liu, J R: 1 article (09/2019)
5.	Wang, H H: 1 article (09/2019)
6.	Zheng, D: 1 article (09/2019)
7.	Zou, W Y: 1 article (09/2019)
8.	Chen, Jing: 1 article (12/2004)
9.	Gu, Long-jun: 1 article (12/2004)
10.	Pan, Ci: 1 article (12/2004)

Related Diseases

1.	Neoplasms (Cancer) 09/14/2019 - "Conclusion: HDM conditioning regimen is superior to CVB regimen in hematological side effects, tumor burden reduction and administration convenience. "
2.	Hodgkin Disease (Hodgkin's Disease) 12/01/2004 - "Conditioning regimen was CBV protocol (cyclophosphamide + bischloro-nitrosourea, i.e., BCNU + etopside) in two children with Hodgkin's disease and etopside plus carboplatin plus melphalan in others. " 02/01/1995 - "After standard high-dose chemotherapy with cyclophosphamide, etoposide and BCNU (CVB regimen for patients with Hodgkin's disease) or BCNU, etoposide, cytosine arabinoside and melphalan (BEAM regimen for patients suffering from non-Hodgkin's lymphoma) followed by autologous BMT, r-metHuG-CSF was administered by continuous intravenous infusion from the first day after autologous BMT until neutrophil recovery. "
3.	Interstitial Lung Diseases (Interstitial Lung Disease) 05/01/1993 - "The main toxicity encountered with the CVB regimen was interstitial pneumonia (IP), seen in four of 15 patients (27%) receiving > or = 600 mg/m2 of BCNU. "
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/01/1995 - "After standard high-dose chemotherapy with cyclophosphamide, etoposide and BCNU (CVB regimen for patients with Hodgkin's disease) or BCNU, etoposide, cytosine arabinoside and melphalan (BEAM regimen for patients suffering from non-Hodgkin's lymphoma) followed by autologous BMT, r-metHuG-CSF was administered by continuous intravenous infusion from the first day after autologous BMT until neutrophil recovery. "

Related Drugs and Biologics

1.	Carmustine (FIVB)
2.	Melphalan (Alkeran)
3.	Cyclophosphamide (Cytoxan)
4.	Carboplatin (JM8)
5.	Etoposide (VP 16)
6.	Cytarabine (Cytosar-U)
7.	Filgrastim (Neupogen)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Drug Therapy (Chemotherapy)
3.	BEAM regimen